Atrial Fibrillation
Conditions
Brief summary
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
Detailed description
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital, on 100 patients with AF and structural heart disease. AF is confirmed by electrocardiography. The patients were divided into 2 groups: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin. Group B (control group): 50 patients received amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Interventions
DRUGEplereone
Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously
Exclusion criteria
* Patients with rheumatic heart disease. * Thyroid dysfunction. * Wolf-Parkinson-White (WPW) syndrome. * Renal impairment. * Hyperkalemia. * Acute coronary syndrome. * Pregnancy. * Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%. * On current use of eplerenone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AF recurrence | 6 months |
Countries
Egypt
Outcome results
None listed